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INTRODUCTION
Central neurocytoma (CN) is an extremely rare neuroepi-
thelial tumor that accounts for 0.1–0.5% of all adult primary 
brain tumors [1-5]. CN is classified by the World Health Or-
ganization as a grade II (benign) neoplasm [3,6]. By defini-
tion, CN is located in the ventricular system. As such, patients 
often present with headaches, nausea, or vomiting consistent 
with an obstructive pattern of hydrocephalus [3,4,7-17]. Com-
puted tomography images demonstrate a heterogeneously 
hyperdense, enhancing mass. CN is typically isointense, iso-
hyperintense and moderately hyperintense on T1-, T2-, and 
contrast enhanced magnetic resonance imaging, respectively 
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Central neurocytoma (CN) typically presents as an intraventricular mass causing obstructive hydro-
cephalus. The first line of treatment is surgical resection with adjuvant conventional radiotherapy. Ste-
reotactic radiosurgery (SRS) was proposed as an alternative therapy for CN because of its lower risk 
profile. The objective of this systematic analysis is to assess the efficacy of SRS for CN. A systematic 
analysis for CN treated with SRS was conducted in PubMed. Baseline patient characteristics and 
outcomes data were extracted. Heterogeneity and publication bias were also assessed. Univariate 
and multivariate linear regressions were used to test for correlations to the primary outcome: local 
control (LC). The estimated cumulative rate of LC was 92.2% (95% confidence interval: 86.5-95.7%, 
p<0.001). Mean follow-up time was 62.4 months (range 3-149 months). Heterogeneity and publica-
tion bias were insignificant. The univariate linear regression models for both mean tumor volume and 
mean dose were significantly correlated with improved LC (p<0.001). Our data suggests that SRS 
may be an effective and safe therapy for CN. However, the rarity of CN still limits the efficacy of a 
quantitative analysis. Future multi-institutional, randomized trials of CN patients should be considered 
to further elucidate this therapy.
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[4,8,11,15,17-21].
Management of CN involves surgical resection and/or ad-
juvant treatment consisting of radiotherapy or chemotherapy. 
Gross total resection (GTR) is often curative, with a 99% 
5-year survival rate [4,12,22-25]. However, due to its central 
location, GTR is rarely achieved (30% to 50% of cases) [26,27]. 
Thus, subtotal resection (STR) with adjuvant treatment is of-
ten necessary [4,12,26,28]. Adjuvant therapy for CN tradi-
tionally consisted of conventional radiotherapy, but was limit-
ed by associated cognitive deficits and other neurotoxicities 
[22,27,29-33]. Recently, stereotactic radiosurgery (SRS) is in-
creasingly utilized as an alternative modality because of fewer 
fractions and associated toxicities [5,22,27,31,34-48]. Several 
studies have demonstrated equivalent tumor control and fewer 
complications with adjuvant SRS when compared with con-
ventional radiotherapy [12,49].
A quantitative systematic review by Park and Steven [22] in 
2012 (62 patients) demonstrated the efficacy of SRS for CN. 
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The current systematic analysis updates the findings of Park 
and includes several additional case series published since then 
for a total of 150 patients [50-53]. To our knowledge, this study 
represents the largest and most current review of CN patients 
treated with SRS.
MATERIALS AND METHODS
Search strategy
Adherence to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (http://www.prisma-statement.
org) was maintained throughout this study. The PubMed da-
tabase was searched by two independent authors using terms 
“CN” and “radiosurgery.” Abstracts were reviewed and screened 
against inclusion and exclusion criteria. Inclusion criteria were: 
1) original data, 2) sufficient data on SRS outcomes for treat-
ment of CN, and 3) more than one patient. Exclusion criteria 
were: 1) non-English text, 2) review articles, and 3) studies 
from the institutions/utilizing the same patient pool already 
included in analysis. Our screening process is summarized in 
Fig. 1.
 
Statistical analysis
Statistical analysis was performed using Comprehensive 
Meta-Analysis software (version 3.0; Biostat, Englewood, NJ, 
USA). The Q Statistic of the χ2 value test and inconsistency in-
dex was used to estimate heterogeneity of included studies. A 
random-effect model was chosen to better account for hetero-
geneity between included studies. A funnel plot, Begg’s rank 
correlation test, and Egger’s linear regression method were 
used to graphically and quantitatively assess publication bias. 
The summary of local control (LC) rate and 95% confidence 
interval (CI) were calculated from reported pooled data. Sen-
sitivity analysis was done to see if any individual study signifi-
cantly affected our results.
Additional univariate and multivariate analyses were com-
pleted using the Statistical Analysis System (SAS, version 9.3; 
SAS Institute Inc., Cary, NC, USA). Linear regression of the 
overall data was used to test if various predictive variables 
were correlated with patient outcomes. Independent variables 
analyzed included mean tumor volume and dose. Data collat-
ed from individual articles was also analyzed using N-1 Pear-
son chi-squared tests to compare proportions [54,55]. Statisti-
cal significance was set at a p-value less than 0.05.
RESULTS
A total of 10 studies (all case series) comprising 150 pa-
tients were included in our quantitative synthesis. These pa-
tients were treated with either Gamma Knife radiosurgery 
(GKRS; n=146, 97%) or linear accelerator radiosurgery (n=4, 
3%) (Table 1). Resection (STR or GTR) was previously per-
formed in 125 patients (83.3%), while 25 patients (16.7%) were 
treated with primary SRS. Mean marginal dose was 14.7 Gy 
(range 9–25 Gy). Mean tumor volume was 9.3 mL (range 0.4–
36.4 mL). Complications included intracerebral (tumoral) 
hemorrhage (n=3), cerebral edema (n=3), and radiation injury 
(n=2). Overall survival was 98% at a mean follow-up of 62.4 
months (range 3–149 months). 
Test of heterogeneity was non-significant (p=0.98). The Q-
value was 2.53 (df=9) and I2=0. Publication bias was assessed 
graphically via funnel plot, which displays no significant asym-
metry (Fig. 2). Begg’s rank correlation test and Egger’s linear 
regression method were both insignificant, with 2-tailed p-
values of 0.09 and 0.93, respectively. Fig. 3 displays the control 
rates of all included studies. Overall LC was 92.2% (95% CI 
86.5–95.7%) (p<0.001).
Univariate linear regression models for both mean tumor 
volume and mean dose were significantly correlated with im-
proved LC. Smaller tumor volumes were associated with better 
overall LC (p<0.001). Likewise, greater radiation doses corre-
lated with better overall LC (p<0.001). 
DISCUSSION
The optimal management of CN remains controversial 
[56]. Schild et al. [12] first reported the use of SRS for CN in 
1997. Since then, multiple case series and systematic reviews 
have reaffirmed its efficacy [5,22,27,31,34-49]. The aforemen-Fig.	1. Flow chart of systematic search process.
Records identified through 
database searching
(n=54)
Additional records identified 
through other sources
(n=0)
Records after duplicates removed
(n=54)
Records screened
(n=54)
Records excluded
(n=33)
Full-text articles 
assessed for eligibility
(n=21)
Studies included in 
qualitative synthesis
(n=10)
Studies included in 
quantitative synthesis 
(meta-analysis)
(n=10)
Full-text articles excluded:
case report, retrospective 
review, or overlapping data 
(n=11)
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tioned study by Park and Steven [22] represents the first quan-
titative systematic review of SRS for treatment of CN. That 
study analyzed 5 retrospective case series (64 CNs in 62 pa-
tients). Of the 62 patients, only 4 displayed tumor growth after 
undergoing SRS (6.3%). We have analyzed 10 retrospective case 
series with a total of 150 patients, making this the largest review 
to date. Park and Steven [22] initially reported a LC rate of 
91.1% with 2 local failures at a mean follow-up of 59.3 months. 
The expanded patient pool used in our study allowed us to 
calculate a similar LC rate (92.2%) reflecting 9 local failures at 
a mean follow-up of 62.4 months. Our data supports the con-
clusion that SRS is a viable treatment for CN.
The two LC failures in Park and Steven’s [22] initial review 
were associated with unknown etiology and inadequate dos-
ing. In our analysis, individual data was available for 4 of the 9 
LC failures. Mean marginal dose for local recurrences was 12.8 
Gy compared to 15.6 Gy in 62 reported patients achieving tu-
mor control. In addition, we found that mean dose was sig-
nificantly correlated with LC. Despite the small sample size, 
this provides evidence that radiation dose could contribute to 
LC. Matsunaga et al. [5] reported improved LC with relatively 
low marginal doses of 13 to 18 Gy and therefore recommend a 
marginal dose of at least 13 Gy for effective tumor control. Our 
findings corroborate the recommendation of Matsunaga et al. 
[5] to maintain a dose high enough to achieve tumor control 
but not so high as to cause toxicity. This is largely consistent 
with the studies we reviewed, which have an overall mean 
dose of 14.7 Gy (range 10.5–17.0 Gy) (Table 1).
MIB-1 (Ki-67) labeling index has been demonstrated to be 
the most important marker of potentially malignant behav-
ior in CN [4,56-64]. CN is considered atypical if the MIB-1 
(Ki-67) labeling index is greater than or equal to 2% [4,57,58]. 
Interestingly, Genc et al. [56] reported that MIB-1 (Ki-67) in-
dices had no significant effect on tumor response to SRS. 
However, the authors acknowledge that interpretation of their 
findings may be limited by a short follow-up duration (mean 36 
months), particularly of atypical CNs. Data on MIB-1 (Ki-67) 
labeling index was not available for most studies, which pre-
vented further analyses with regard to index and LC.
SRS has been demonstrated to be effective in primary man-
agement of CN, particularly in cases less amenable to surgical 
resection [29,31,50]. In our study, 25 patients (16.7%) were 
treated with GKRS alone. Individual patient data was available 
for 18 patients. We found similar LC between primary SRS 
and our overall cohort (88.9% vs. 92.2%, p=0.63). Kim et al. [29] 
report a 20% LC failure rate for patients treated with primary 
SRS vs. 40% LC failure in patients treated with adjuvant SRS. 
Similarly, Karlsson et al. [50] found primary SRS to be effica-
cious in control of incidental, asymptomatic CN. The report of 
effective primary control is consistent with our findings that 
mean tumor volume is directly correlated with LC failure, since 
smaller tumor volumes are less likely to need surgical decom-
Table	1. Literature review of SRS for central neurocytoma 
Author and year [ref] n
Mean 
age
Modality
MTV 
(mL)
Mean 
dose (Gy)
F/U 
(mos)
RR 
(%)
LC 
(%)
DC 
(%)
OS 
(%)
Complications
Yamanaka et al., 2016 [53] 036 35.0 GKRS 0*4.9* *15.0* *54.5* 088 094 092 097 Tumor hemorrhage×2, radiation injury×1
Monaco et al., 2015 [52] 008 29.0 GKRS 05.5 14.6 63.3 088 100 088 100 –
Kim et al., 2013 [29] 020 32.0 GKRS 11.0 15.4 103 070 085 085 100 Edema×1
Karlsson et al., 2012 [50] 042 32.0 GKRS 12.0 13.0 073 091 095 095 100 Edema×1
Genc et al., 2011 [56] 022 30.2 GKRS 13.4 16.4 036 095 095 100 100 –
Yen et al., 2007 [46] 007 26.7 GKRS 06.0 16.0 060 100 100 100 086 Tumor hemorrhage×1
Martín et al., 2003 [41] 004 26.3 LINAC 03.2 16.5 033 100 100 100 100 Alopecia, edema, necrosis×1
Anderson et al., 2001 [27] 004 28.3 GKRS 07.0 17.0 017 100 100 100 100 –
Bertalanffy et al., 2001 [34] 003 22.3 GKRS 03.9 12.8 060 100 100 100 067 –
Cobery et al., 2001 [35] 004 27.5 GKRS 14.8 10.5 044 100 100 100 100 –
Total 150
Mean 31.5 09.3 14.7 62.4 089 094 094 098
*Median. GKRS, Gamma Knife radiosurgery; LINAC, linear accelerator; MTV, mean tumor volume; Gy, Gray; F/U, follow-up; RR, recur-
rence rate; LC, local control; DC, distant control; OS, overall survival; SRS, stereotactic radiosurgery
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Fig.	2. Funnel plot of included studies showing asymmetry.
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pression or be symptomatic. Moreover, our data suggests that 
smaller tumor volume is significantly correlated with better 
LC.
Radiation associated adverse events (AREs), defined as hy-
perintensity surrounding the treated lesion on imaging, are 
rare after SRS for CN (Table 1) [52]. There are only 3 reported 
AREs (all cases of cerebral edema) in the literature with only 
one becoming symptomatic (Table 1) [29,41,50]. Only 2% of 
the patients reviewed experienced AREs. Interestingly, Karls-
son et al. [50] also reported that 45% (19/42) of their patients 
developed ventricular enlargement with 33% (1/3) requiring 
surgical management. This has not been reported elsewhere 
in the literature. Long term outcomes and toxicities of SRS for 
CN are not known. There have been two reported cases of in-
creased MIB-1 (Ki-67) index, angiogenesis and glial differen-
tiation in recurrent tumor that may have been attributable to 
SRS [5,65]. Given the low complication rate and favorable tu-
mor control, current dosages reported are considered both 
safe and effective, respectively.
Limitations to this study were ever-present despite an in-
crease in sample size (>two-fold) as compared to the prior 
quantitative systematic review. The rarity of CN makes avail-
able data sporadic, consisting of only case series. Mean follow-
up for the included studies is another limitation, as a limited 
window can blind our results to potential failures occurring af-
ter end-of-study (Table 1). 
CONCLUSION
Our data suggests that SRS may be an effective and safe ther-
apy for CN. The rarity of CN limits the efficacy of a quantitative 
analysis. Future prospective, randomized studies with extend-
ed follow-up should be conducted to elucidate long-term effi-
cacy of SRS in treatment of typical and atypical CN.
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